The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 1 µg/ml. Detects a band of approximately 46 kDa (predicted molecular weight: 46 kDa).
FunctionInvolved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP). Isoform 2 lacks activity is an dominant-negative inhibitor of caspase-9.
Tissue specificityUbiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes.
Sequence similaritiesBelongs to the peptidase C14A family. Contains 1 CARD domain.
Developmental stageExpressed at low levels in fetal heart, at moderate levels in neonate heart, and at high levels in adult heart.
Post-translational modificationsCleavages at Asp-315 by granzyme B and at Asp-330 by caspase-3 generate the two active subunits. Caspase-8 and -10 can also be involved in these processing events.
Caspase 9 apoptosis related cysteine peptidase antibody
Caspase 9 Dominant Negative antibody
Caspase 9c antibody
Caspase-9 subunit p10 antibody
ICE LAP6 antibody
ICE like apoptotic protease 6 antibody
ICE-like apoptotic protease 6 antibody
protein phosphatase 1, regulatory subunit 56 antibody
References for Anti-Caspase-9 antibody [5B4] (ab28131)
This product has been referenced in:
Savry A et al. Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment. Neoplasia15:49-60 (2013).
Read more (PubMed: 23358890) »
López-Huertas MR et al. The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes: a potential mechanism for persistent viral production. J Biol Chem288:7626-44 (2013).
Read more (PubMed: 23364796) »